Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class

AMG 133 For Obesity Is One To Watch In CV Portfolio

 
• By Mandy Jackson
  
Human heart with blood vessels
About 20% of people have elevated Lp(a) levels that increase their cardiovascular disease risk • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D